Such collaboration enhances diagnostic accuracy, prevents unnecessary follow-ups, and maintains patient trust in the healthcare system
Robust evidence shows the effects of bromocriptine treatment in type 2 diabetes
Safety Warning Consult a healthcare professional before use
View the current JRNYS program details (official JRNYS page) JRNYS GLP-1 Medication Options: Semaglutide, Tirzepatide, Liraglutide, Ozempic, Mounjaro, Wegovy, and Zepbound JRNYS-affiliated providers may discuss and prescribe medications across several GLP-1 and related categories
**This product requires 0.6% Acetic Acid Solution for reconstitution
Current diabetes guidelines recommend multifactorial CV risk management and the preferential use of a glucagon-like peptide-1 receptor agonist (GLP-1RA) or sodiumglucose cotransporter-2 inhibitor with proven CV benefits as a first choice add-on to metformin in patients with T2D and established atherosclerotic CVD [2, 4]